Pharmacologic Relapse Prevention for Alcoholic Smokers

Phase 2

Completed

• Conditions: Alcoholism; Smoking
• Interventions: Drug: Placebo; Drug: bupropion (Wellbutrin)

• Registration Number: NCT00000457
• Lead Sponsor: Mayo Clinic

Brief Summary

This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.

Detailed Description

The purpose of this trial was to recruit 292 recovering alcoholic smokers (abstinent from alcohol for a minimum of 1 year), who want to stop smoking and provide them with 100% nicotine replacement. The 100% nicotine replacement will be undertaken using a nicotine patch. By measuring their nicotine levels at study entry we can determine the patch dosing needed. The patch dosing will vary from 22 mg to 44 mg. Those who are able to achieve tobacco abstinence by week 8 will enter a relapse prevention phase for the remaining 44 weeks. In this phase, they will be randomized to active or placebo bupropion (300 mg/day). After 44 weeks of the relapse prevention trial (at week 52 of study participation), they will enter a post medication follow up for 6 months.

Study Timeline

• Study Start: 1998-06
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 1999-11-02
• Study First Posted: 1999-11-03
• Primary Completion: 2002-04
• Study Completion: 2007-08
• Status Verified: 2013-10
• Last Update Submitted: 2013-10-18
• Last Update Posted: 2013-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 195

Inclusion Criteria

• History of alcohol dependence and at least one year of abstinence from alcohol intake.
• Has a history of smoking 20 or more cigarettes per day for the prior year.
• Can read and write English.
• Stated ability to fully participate in the study and keep all scheduled appointments.
• Has provided written informed consent.
• General good health.

Exclusion Criteria

• Recent history (within three months) of a clinically significant myocardial infarction, unstable angina pectoris, serious cardiac arrhythmia or any other medical condition which the physician investigator deems incompatible with study participation.
• Current major depression. A past history of major depression will not be an exclusionary criteria.
• Current or previous use of bupropion (Wellbutrin).
• Active non- nicotine drug dependence.
• Past or current history of bipolar disorder, pain disorder or psychosis, schizophrenia, or other major psychiatric disorders.
• Current medically indicated use of psychiatric drugs.
• Females who are pregnant, lactating, or likely to become pregnant during the first year which includes the nicotine patch and bupropion (Wellbutrin) phase.
• History of severe skin allergies or evidence of severe chronic skin disorders.
• Current use of nicotine containing medication or tobacco products other than cigarettes.
• Current use (within 30 days of initiation of patch therapy) of the following medications for smoking cessation: clonidine, buspirone, or doxepin.
• A predisposition to seizures.
• A history of or current diagnosis of anorexia nervosa or bulimia.
• Medical disorder that would interfere with the absorption, metabolism, or excretion of bupropion (Wellbutrin).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
Bupropion	bupropion (Wellbutrin)	Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.

Primary Outcome Measures

Name	Time	Method
Will bupropion reduce relapse to smoking compared to placebo	52 weeks and 76 weeks	Determine if long-term use of bupropion will reduce the rate of relapse to smoking compared to placebo in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy projected to achieve 100% replacement.

Secondary Outcome Measures

Name	Time	Method
Does matching the dose of nicotine patches to nicotine levels help increase smoking abstinence	8 weeks	Determine the week 8 smoking cessation rate in recovering alcoholics provided a nicotine patch dose projected to achieve 100% replacement.

Trial Locations

Locations (1)

Mayo Clinic Rochester; 🇺🇸 Rochester, Minnesota, United States